FijiTuberculosis profile
Population  2018 <1 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 0.48 (0.37–0.61) 54 (42–69)
HIV-positive TB incidence 0.025 (0.014–0.04) 2.9 (1.6–4.5)
MDR/RR-TB incidenceºº <0.01 (<0.01–<0.01) 0.35 (0.2–0.54)
HIV-negative TB mortality 0.038 (0.037–0.038) 4.2 (4.2–4.3)
HIV-positive TB mortality <0.01 (<0.01–<0.01) 0.6 (0.31–0.97)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 0.68% (0.02–3.7)
Previously treated cases 0% (0–34)
TB case notifications, 2018  
Total new and relapse 385
          - % tested with rapid diagnostics at time of diagnosis 95%
          - % with known HIV status 89%
          - % pulmonary 68%
          - % bacteriologically confirmedººº 55%
          - % children aged 0-14 years 20%
          - % women 34%
          - % men 46%
Total cases notified 389
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)
TB patients facing catastrophic total costs, 2017 40% (33–47)
TB case fatality ratio (estimated mortality/estimated incidence), 2018 9% (7–11)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 18 5%
          - on antiretroviral therapy 17 94%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 110%
          - Previously treated cases 100%
Laboratory-confirmed cases* MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment* ** MDR/RR-TB: 1, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 81% 352
Previously treated cases, excluding relapse, registered in 2017 86% 7
HIV-positive TB cases registered in 2017 89% 9
MDR/RR-TB cases started on second-line treatment in 2016 100% 1
XDR-TB cases started on second-line treatment in 2016   0
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100%
TB financing, 2019  
National TB budget (US$ millions) 1.3
Funding source: 80% domestic, 2% international, 19% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-12-07 Data: www.who.int/tb/data